URL : https://gphin.canada.ca/cepr/showarticle.jsp?docId=1006887653
ID : GPHN2020050100265

Date : 2020-05-01 12:04:00
Title : Glenmark to Conduct Trial of Favipiravir as COVID-19 Treatment
Ariticle : 
Mumbai-based Glenmark Pharmaceuticals received approval for a clinical trial in India of its antiviral favipiravir as a potential COVID-19 treatment.
The initial 28-day trial will assess the influenza drug in 150 subjects with mild-to-moderate COVID-19 infections, randomized to receive either favipiravir or standard care.
Glenmark is the first drugmaker in India approved to test a potential COVID-19 treatment.
Release date: 20200501